Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2011 Jan;33(1):135-44. doi: 10.1016/j.clinthera.2011.01.012.

2.

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Law MR, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2010 Apr;32(4):729-41; discussion 716. doi: 10.1016/j.clinthera.2010.04.007.

4.

Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.

Adams AS, Zhang F, LeCates RF, Graves AJ, Ross-Degnan D, Gilden D, McLaughlin TJ, Lu C, Trinacty CM, Soumerai SB.

Arch Intern Med. 2009 Apr 27;169(8):750-6. doi: 10.1001/archinternmed.2009.39.

5.

Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.

Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS.

Med Care. 2010 Jan;48(1):4-9. doi: 10.1097/MLR.0b013e3181bd4c10.

PMID:
19956079
6.
7.

Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.

Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB.

Psychiatr Serv. 2009 Apr;60(4):520-7. doi: 10.1176/appi.ps.60.4.520.

PMID:
19339328
9.

Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

Law MR, Ross-Degnan D, Soumerai SB.

Psychiatr Serv. 2008 May;59(5):540-6. doi: 10.1176/ps.2008.59.5.540.

PMID:
18451014
10.

Differences in the cost of antidepressants across state Medicaid programs.

Kelton CM, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ.

J Ment Health Policy Econ. 2008 Mar;11(1):33-47.

PMID:
18424875
11.

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA.

Clin Ther. 2008 Aug;30(8):1524-39; discussion 1506-7. doi: 10.1016/j.clinthera.2008.08.009.

PMID:
18803994
12.

Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.

Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW.

Clin Ther. 2004 Sep;26(9):1518-32.

PMID:
15531015
13.
14.

Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.

Adams AS, Madden JM, Zhang F, Soumerai SB, Gilden D, Griggs J, Trinacty CM, Bishop C, Ross-Degnan D.

Med Care. 2014 Aug;52(8):695-703. doi: 10.1097/MLR.0000000000000159.

15.

Evidence Brief: The Quality of Care Provided by Advanced Practice Nurses.

McCleery E, Christensen V, Peterson K, Humphrey L, Helfand M.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2014 Sep.

16.

Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.

Walthour A, Seymour L, Tackett R, Perri M.

Ann Pharmacother. 2010 May;44(5):809-18. doi: 10.1345/aph.1M620.

PMID:
20388858
17.

Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.

Amin K, Farley JF, Maciejewski ML, Domino ME.

J Manag Care Spec Pharm. 2017 Mar;23(3):337-345. doi: 10.18553/jmcp.2017.23.3.337.

18.

Persistence of use of lipid-lowering medications: a cross-national study.

Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J.

JAMA. 1998 May 13;279(18):1458-62.

PMID:
9600480
19.

Supplemental Content

Support Center